SCHEMBL1664702

SCHEMBL1664702

N#CCn1cccc1C(=O)Nc1ccc(C(=O)c2ccc(NC(=O)c3ccc(N4CCC(O)CC4)cc3Cl)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ATM Q13315 1/20 0.42
RAB9A P51151 5/20 0.40
NPC1 O15118 2/20 0.40
HPGDS O60760 1/20 0.39
MAPT P10636 5/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD11B1 P28845 2/20 0.37
ALDH1A1 P00352 1/20 0.36
LRRK2 Q5S007 1/20 0.36
AR P10275 1/20 0.35
PKM P14618 1/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664698 0.90 HPGDS (0.38) RAB9ANPC1HPGDSAR
SCHEMBL1665814 0.89 RAB9A (0.44) MEN1KMT2AATMRAB9ANPC1
SCHEMBL8771316 0.88 HPGDS (0.46) MEN1KMT2AATMRAB9ANPC1
SCHEMBL1663722 0.85 HPGDS (0.53) MEN1KMT2AATMRAB9ANPC1
SCHEMBL1666388 0.83 HPGDS (0.46) MEN1KMT2AATMRAB9ANPC1
SCHEMBL1664185 0.82 KMT2A (0.44) MEN1KMT2AATMRAB9ANPC1
SCHEMBL1666384 0.82 HPGDS (0.48) RAB9ANPC1HPGDSMAPTGAA
SCHEMBL1664929 0.77 HPGDS (0.55) MEN1KMT2AATMRAB9ANPC1
SCHEMBL8770806 0.76 HPGDS (0.50) MEN1KMT2AATMRAB9ANPC1
SCHEMBL1663537 0.76 HPGDS (0.55) MEN1KMT2ARAB9ANPC1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL MEN1 1370/4885KMT2A 2225/4885ATM 3747/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885ATM 2698/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885ATM 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.